专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230091568A1 OPHTHALMIC DRUG SUSTAINED RELEASE FORMULATION AND USES THEREOF 有权
公开(公告)号：US20230091568A1
公开(公告)日：2023-03-23
申请号：US17740192
申请日：2022-05-09
申请人： Mati Therapeutics, Inc.
发明人： Deepank Utkhede , Catherine JONES , David J. Wiseman
IPC分类号： A61K9/00 , A61F9/00 , A61F9/007 , A61K9/14 , A61K31/165 , A61K31/569 , A61K31/573 , A61K38/13 , A61K47/10 , A61K47/34
摘要： A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

2. 发明申请

US20150133546A1 SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS 审中-公开
公开(公告)号：US20150133546A1
公开(公告)日：2015-05-14
申请号：US14599463
申请日：2015-01-17
申请人： Mati Therapeutics Inc.
发明人： Zuhal Butuner , Deepank Utkhede , Sylie Sim , David J. Wiseman
IPC分类号： A61K9/00 , A61K31/165 , A61F9/00 , A61K47/24 , A61F9/007 , A61K31/216 , A61K47/34
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K31/165 , A61K31/216 , A61K31/5575 , A61K45/06 , A61K47/24 , A61K47/34
摘要： The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.

3. 发明申请

US20150064230A1 SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS 审中-公开
标题翻译：持续发布一个或多个代理
公开(公告)号：US20150064230A1
公开(公告)日：2015-03-05
申请号：US14468262
申请日：2014-08-25
申请人： Mati Therapeutics Inc.
发明人： Zuhal Butuner , Deepank Utkhede , Sylie Sim , David J. Wiseman
IPC分类号： A61K9/00 , A61F9/007 , A61K47/24 , A61K47/34 , A61K31/216
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K31/165 , A61K31/216 , A61K31/5575 , A61K45/06 , A61K47/24 , A61K47/34
摘要： The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.
摘要翻译：本文所述的泪道植入物递送系统和方法提供用于治疗疾病的治疗剂的受控释放，包括用拉坦前列素或其他抗青光眼剂治疗青光眼，高眼压症或升高的眼内压。还提供了使用拉坦前列素或其他抗青光眼药物与渗透促进剂如苯扎氯铵和/或人造泪液联合治疗疾病，包括青光眼，高眼压症或升高的眼内压。还提供了植入物，其含有与患者眼睛相邻的泪点中的药物核心，用于控制释放治疗剂如拉坦前列素用于治疗青光眼，所述药物核心含有聚合物如交联的硅氧烷，治疗剂药剂和赋形剂，其中所述赋形剂可以增加药剂从药物核心释放的速率，或者可以增加芯体中的药物负载，而不损失药物在芯内的理想均匀性，或者可以改善药剂在眼睛或泪液中，或者可以增加药剂对眼睛的角膜穿透。

4. 发明申请

US20210023165A1 OPHTHALMIC DRUG SUSTAINED RELEASE FORMULATION AND USES FOR DRY EYE SYNDROME TREATMENT 有权
公开(公告)号：US20210023165A1
公开(公告)日：2021-01-28
申请号：US17043255
申请日：2019-03-29
申请人： Mati Therapeutics, Inc.
发明人： Deepank Utkhede , David J. Wiseman
IPC分类号： A61K38/13 , A61K47/34 , A61K9/00
摘要： A solid matrix sustained release ophthalmic formulation for topical delivery of the ophthalmic drug cyclosporine to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period are provided herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式